NCT01981954View on ClinicalTrials.gov

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 25, 2013

Primary Completion Date

December 18, 2015

Study Completion Date

December 18, 2015

Conditions

Neurogenic Detrusor OveractivityPediatric

Interventions

DRUG

Solifenacin succinate

Oral suspension

Trial Locations (8)

1015

Site PH6301 Philippines Children's Medical Center, Manila

9000

Site BE3203 Gent University Hospital, Ghent

10591

Site US1008 Pediatric Urology Associates, P.C., Tarrytown

110744

Site KR8207 Seoul National University Hospital, Seoul

120752

Site KR8201 Severance Hospital, Seoul

81-211

Site PL4803 Uniwersyteckie Centrum Kliniczne, Gdansk

04-730

Site PL4801 Pomnik-Centrum Zdrowia Dziecka, Warsaw

S10 2TN

Site GB4401 Sheffield Children's Hospital, Sheffield

All Listed Sponsors

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01981954 - A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) | Biotech Hunter | Biotech Hunter